Algeta to Present at BioEquity Europe 2007 Conference
Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that Dr. Thomas Ramdahl, President and CEO of Algeta, will give a corporate presentation at the upcoming BioEquity Europe 2007 Conference in Glasgow, Scotland.
The presentation will be on Monday, 21 May at 12:30 BST (UK). The conference is being held at the Radisson SAS Hotel in Glasgow.
In his presentation, Dr. Ramdahl will discuss the significant progress Algeta has made in the clinical development of its lead product candidate, Alpharadin. In Phase II trials, Alpharadin treatment has demonstrated a statistically significant survival benefit in patients with metastatic, hormone-refractory prostate cancer, as well as a benign side effect profile. Algeta is currently preparing Alpharadin to enter Phase III trials in 2008.
Dr. Ramdahl will also discuss Algeta’s unique technology platform for the development of a pipeline of internally targeted alpha particle based radiotherapies as potential new treatments for a range of cancers.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.